<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Elliott, Victor</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Differential Effects of ACE Inhibitors and ARBs on Mortality in Patients with Hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">The primary goal of hypertension management is to reduce associated morbidity and mortality. This article discussed the differences in mortality and morbidity outcomes for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Specific trials include ACCOMPLISH, ASCOT-BPLA, EUROPA, VALUE, VALIANT, ONTARGET, and ELITE II.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>